Zepbound (Tirzepatide) superior to Wegovy (semaglutide), says a clinical trial funded by Lilly, clinical trial

Zepbound (Tirzepatide), produced by Fortune 500 Eli Lilly & Co., beat the competitor Wegovy (semaglutide), a product of the global 500 company Novo Nordisk, in a randomized clinical trial 2023–24.

Shelby Knowles – Bloomberg/Getty Images